Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.82 USD | +0.48% | +6.33% | +18.56% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.56% | 557.71Cr | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.70% | 2.13TCr | |
-6.03% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+5.10% | 1.39TCr | |
+37.57% | 1.25TCr |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Insider Sell: Halozyme Therapeutics